AstraZeneca is to invest $3.5 billion in the USA focused on expanding the Company’s research and manufacturing footprint by the end of 2026.

AstraZeneca’s investment will be allocated to a R&D centre in Massachusetts, a next generation manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts and specialty manufacturing in Texas.